Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
LTGO has been the topic of several other reports. Leerink Partners initiated coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $73.00 price objective for the company. Guggenheim initiated coverage on shares of Latigo Biotherapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $50.00 target price on the stock. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $52.25.
Read Our Latest Research Report on LTGO
Latigo Biotherapeutics Stock Performance
Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last issued its quarterly earnings data on Thursday, September 3rd. The company reported ($27.59) EPS for the quarter.
Insider Transactions at Latigo Biotherapeutics
In other Latigo Biotherapeutics news, major shareholder Foresite Capital Management V, acquired 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James B. Tananbaum acquired 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the acquisition, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.
Latigo Biotherapeutics Company Profile
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for the treatment of acute and chronic pain. The company focuses on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of developing therapies that may provide pain relief without the risks associated with opioid medications.
Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, led by LTG-001 for acute pain and additional research programs aimed at chronic pain conditions.
Further Reading
- Five stocks we like better than Latigo Biotherapeutics
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
